Figure 1.

Design of a phase I dose‐escalation study of propagermanium (PG) used as an antimetastatic drug for perioperative patients with primary breast cancer

Design of a phase I dose‐escalation study of propagermanium (PG) used as an antimetastatic drug for perioperative patients with primary breast cancer